Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors

Endocrine Practice

Volumn 18, Issue 2, 2012, Pages 140-145

  Varanasi, Ajay ^a   Patel, Pavan ^a   Makdissi, Antoine ^a   Dhindsa, Sandeep ^a   Chaudhuri, Ajay ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; EXENDIN 4; HEMOGLOBIN A1C; LIRAGLUTIDE; TRIACYLGLYCEROL;

ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DISEASE DURATION; GLYCEMIC CONTROL; HEART PROTECTION; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 84859867948     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11169.OR     Document Type: Article

References (18)

1. Bode B. Liraglutide: A review of the first once-daily GLP-1 receptor agonist. Am J Manag Care. 2011;17(2 suppl):S59-S70.
2. Astrup A, Rössner S, Van Gaal L, et al (NN8022-1807 Study Group). Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study [published correction appears in Lancet. 2010;375:984]. Lancet. 2009;374:1606-1616.
3. Nauck M, Frid A, Hermansen K, et al (LEAD-2 Study Group). Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32:84-90.
4. Zinman B, Gerich J, Buse JB, et al (LEAD-4 Study Investigators). Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) [published correction appears in Diabetes Care. 2010;33:692]. Diabetes Care. 2009;32: 1224-1230.
5. Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: Onset of treatment effects over time. Int J Clin Pract. 2010;64:267-276.
6. Jendle J, Nauck MA, Matthews DR, et al (LEAD-2 and LEAD-3 Study Groups). Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163-1172.
7. Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract. 2007;13:444-450.
8. Varanasi A, Chaudhuri A, Dhindsa S, et al. Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations. Endocr Pract. 2011;17:192-200.
9. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists [published online ahead of print December 19, 2010]. Cardiovasc Ther. doi:10.1111/ j.1755-5922.2010.00256.x.
10. Buse JB, Rosenstock J, Sesti G, et al (LEAD-6 Study Group). Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
11. Buse JB, Sesti G, Schmidt WE, et al (Liraglutide Effect and Action in Diabetes-6 Study Group). Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33:1300-1303.
12. Jellinger PS. Focus on incretin-based therapies: Targeting the core defects of type 2 diabetes. Postgrad Med. 2011; 123:53-65.
13. Hallberg P, Schwan S, Melhus H. Liraglutide for weight loss in obese people [with author reply]. Lancet. 2010;375: 551-553.
14. Wu JD, Xu XH, Zhu J, et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:143-148.
15. Derosa G, Maffioli P, Salvadeo SA, et al. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010;12:233-240.
16. Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent anti-inflammatory action. Presented at: American Diabetes Association 71st Annual Meeting and Scientific Sessions; June 24-28, 2011; San Diego, CA. Abstract 970-P.01-D.
17. Courrèges JP, Vilsbøll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med. 2008;25:1129-1131.
18. Dandona P, Chaudhuri A, Dhindsa S. A novel antihypertensive effect of exenatide, a GLP-1 agonist. Am J Hypertens. 2010;23:228.